ClinicalTrials.gg
CompletedNCT01276353Updated Aug 8, 2014Results posted

A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

A Phase 2 interventional study of E2020 and E2020 in Alzheimer's Type Dementia, sponsored by Eisai Inc.. Completed at 11 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
36th of 58
45 · median 79
Started
2011
with 2 others
Phase 2
4 of 60
none open now
Registered
32nd of 60
by date
Lead sponsor
9 of 60
Eisai Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 36th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2011, is one of 4 in phase 2, and was the 32nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.

03

Conditions studied

  • Alzheimer's Type Dementia

Keywords

  • Alzheimer Disease
  • Dementia
  • Delirium
  • Amnestic
  • Cognitive Disorders
  • Donepezil
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Mental Disorders
  • Cholinesterase Inhibitors
  • Enzy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic evidence of probable Alzheimer's disease (AD) consistent with the Diagnostic and Statistical Manual for Mental Disorders-version IV ()
  • Hachinski Ischemic Score
  • Functional Assessment Staging (FAST) scale greater than or equal to 6 at Screening.
  • (MMSE) score of 1 to 12 at Screening
  • Subjects who are on a stable Aricept- dose of 10 mg immediate release (IR), taken as a single, daily dose for 3 months prior to the Screening Visit
  • Evidence consistent with Alzheimer's disease (AD) on any cranial image on magnetic resonance imaging (MRI) or computed tomography (CT) scan or etc. obtained within 24 months prior to the Screening Visit. Subjects who have any observations of dementia other than Alzheimer's type after the last image diagnosis should be reconfirmed.
  • Age 50 years
  • Written is to have been obtained from the subject (if possible) or from the subject's legal guardian or other representative

Exclusion criteria

Exclusion Criteria

  • Subjects with dementia other than Alzheimer's type
  • Subjects with significant neurological or psychiatric disorders such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, a history of head injury with loss of consciousness, or a history of brain surgery followed by persistent deficits
  • Subjects with allergy to donepezil hydrochloride or piperidine derivatives
  • Subjects with a cause of Alzheimer's disease (AD) which is supported by any laboratory tests such as Vitamin B12, folate levels, triiodothyronine, free triiodothyronine, thyroxine, thyroid stimulating hormone (TSH) or serologic test for syphilis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    1

    Drug: E2020

  • Active comparator
    2

    Drug: E2020

Interventions

  • DrugE2020

    Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation

  • DrugE2020

    10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3

    Time frame: Visit 2 [Day1] and Visit 3 [Day 15]

Secondary outcomes

  1. Cmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status

    All subjects were identified as Extensive Metabolizer \[EM\] or Intermediate Metabolizer \[IM\] predicted from their CYP2D6 phenotypes. Ultra-rapid Metabolizer (UM) and Poor Metabolizer (PM) were not identified in any subject. Since the analysis population i

    Time frame: Visit 2 [Day1] and Visit 3 [Day 15]

07

Results

Posted Aug 1, 2014

Participant flow

Double-blind
Participant flow — Double-blind
MilestoneE2020 SR 23 mgE2020 10 mg
Started2223
Completed1923
Not completed30
Withdrew: Adverse event20
Withdrew: Withdrawal by subject10
Extension
Participant flow — Extension
MilestoneE2020 SR 23 mgE2020 10 mg
Started1923
Completed1214
Not completed79
Withdrew: Adverse event25
Withdrew: Withdrawal by subject12
Withdrew: Withdrawal of study drug 4 days in a row31
Withdrew: Physician decision10
Withdrew: Prohibited concomitant medications01

Outcome measures

SecondaryCmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status

All subjects were identified as Extensive Metabolizer \[EM\] or Intermediate Metabolizer \[IM\] predicted from their CYP2D6 phenotypes. Ultra-rapid Metabolizer (UM) and Poor Metabolizer (PM) were not identified in any subject. Since the analysis population i

Time frame:
Visit 2 [Day1] and Visit 3 [Day 15]
Reported as:
Mean · ng/mL
Cmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status
ng/mLE2020 SR 23 mgE2020 10 mg (EM)
Visit 2 EM [IR: n=16, SR: n=17]117.999 ± 28.89898.117 ± 32.323
Visit 2 IM [IR: n=5, SR: n=4]161.363 ± 18.761104.294 ± 23.962
Visit 3 EM [IR: n=16, SR: n=15]116.771 ± 31.66363.896 ± 20.662
Visit 2 IM [IR: n=5, SR: n=3]182.953 ± 48.42279.802 ± 24.984
PrimaryMaximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3
Time frame:
Visit 2 [Day1] and Visit 3 [Day 15]
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3
ng/mLE2020 SR 23 mgE2020 10 mg
Visit 2126.503 ± 31.2797.006 ± 32.934
Visit 3127.335 ± 40.65466.081 ± 24

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E2020 SR 23 mg (Double-blind)—0/22 (0%)13/22 (59.1%)
E2020 10 mg (Double-blind)—0/23 (0%)2/23 (8.7%)
E2020 SR 23 mg (Extension)—0/19 (0%)9/19 (47.4%)
E2020 10 mg (Extension)—1/23 (4.3%)16/23 (69.6%)
Most frequent serious events
Most frequent serious events
EventE2020 SR 23 mg (Double-blind)E2020 10 mg (Double-blind)E2020 SR 23 mg (Extension)E2020 10 mg (Extension)
AtaxiaNervous system disorders0/220/230/191/23
Most frequent other events
Showing 10 of 18
Most frequent other events
EventE2020 SR 23 mg (Double-blind)E2020 10 mg (Double-blind)E2020 SR 23 mg (Extension)E2020 10 mg (Extension)
NauseaGastrointestinal disorders3/221/230/197/23
VomitingGastrointestinal disorders4/221/230/197/23
Decreased appetiteMetabolism and nutrition disorders6/220/233/194/23
SomnolenceNervous system disorders2/220/231/194/23
Weight decreasedInvestigations2/220/233/191/23
DiarrhoeaGastrointestinal disorders3/221/232/190/23
Electrocardiogram QT prolongedInvestigations2/220/231/190/23
ConstipationGastrointestinal disorders0/220/230/192/23
Eye DischargeEye disorders0/220/231/190/23
EpulisGastrointestinal disorders0/220/231/190/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)E2020 SR 23 mgE2020 10 mgTotal
Mean79.3 ± 9.873.6 ± 10.876.4 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)E2020 SR 23 mgE2020 10 mgTotal
Female161632
Male6713
Hachinski Score
Hachinski Score(Scores on a Scale)E2020 SR 23 mgE2020 10 mgTotal
Mean1.1 ± 1.30.7 ± 1.10.9 ± 1.2
08

Study locations

11 sites
  • Kitakyushu, Fukuoka, Japan
  • Mizunami, Gifu, Japan
  • Yokosuka, Kanagawa, Japan
  • Sanjo, Niigata, Japan
  • Kurashiki, Okayama, Japan
  • Fuji, Shizuoka, Japan
  • Hachioji, Tokyo, Japan
  • Kodaira, Tokyo, Japan
  • Akita, Japan
  • Fukuoka, Japan
  • Saitama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2011
First posted
Jan 13, 2011
Start
Jan 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Aug 1, 2014
Last update
Aug 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01276353
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 13, 2011
Start date
Jan 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Aug 1, 2014
Last update
Aug 8, 2014

Study contacts

Naoki Kubota
study director · Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion